Opportunities and Threats in the BRIC Pharmaceutical Markets

Opportunities and Threats in the BRIC Pharmaceutical Markets: Assessing the Impact of Recent Pricing, Reimbursement, and Market Access Developments

The “BRIC markets”—Brazil, Russia, India, and China—have been the focus of particular attention from the pharmaceutical industry. Decision Resources tracks pricing, reimbursement, and market access developments in each of these markets and assesses the implications for drug manufacturers seeking to expand their scope into these markets. This white paper describes third-quarter developments and their impact on pharma company strategies.

Please fill out the following form to download this FREE white paper:
*First Name:		*Last Name:
*Title:		*Company Name:
*Phone Number:		*Email Address:
*Please help us understand your areas of interest in Emerging Markets by answering the following optional questions.*
Which emerging markets are of particular interest to you?
Brazil Russia India China South Korea Mexico Turkey Central and Eastern European markets Other:
Which topics related to these markets are of particular interest to you?
Mergers, acquisitions, alliances and partnerships Healthcare system Market trends Pricing, reimbursement and market access Regulatory affairs and legislation Intellectual property rights R&D activity Manufacturing Distribution Sales and marketing Disease market analysis Other:
Which elements would you most like to see in reports on emerging markets?
Epidemiology Physician interviews/surveys Pricing data Sales and prescribing trends Market forecasts Commentaries from local experts
*Agreement:	I have read and agree to abide by the Decision Resources Terms of Use and Privacy Policy.

*Required field

Decision Resources Group brands include: